NasdaqGM - Delayed Quote • USD
Sutro Biopharma, Inc. (STRO)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:46 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 10 | 10 |
| Avg. Estimate | -0.92 | -0.74 | -3.3 | -3.26 |
| Low Estimate | -1.09 | -1.08 | -4.33 | -5.05 |
| High Estimate | -0.72 | -0.03 | -0.76 | -0.74 |
| Year Ago EPS | -0.85 | -0.64 | -1.78 | -3.3 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 9 | 8 |
| Avg. Estimate | 11.92M | 22.51M | 55.83M | 73.54M |
| Low Estimate | 5M | 5.2M | 24M | 24M |
| High Estimate | 24.65M | 69.27M | 129.61M | 204.86M |
| Year Ago Sales | 12.67M | 10.41M | 153.73M | 55.83M |
| Sales Growth (year/est) | -5.90% | 116.20% | -63.70% | 31.70% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.81 | -0.73 | -0.74 | -0.82 |
| EPS Actual | -0.85 | -0.64 | -0.81 | 0.52 |
| Difference | -0.04 | 0.09 | -0.07 | 1.34 |
| Surprise % | -4.90% | 12.30% | -9.50% | 163.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.92 | -0.74 | -3.3 | -3.26 |
| 7 Days Ago | -0.92 | -0.74 | -3.3 | -3.26 |
| 30 Days Ago | -0.91 | -0.92 | -3.87 | -3.7 |
| 60 Days Ago | -0.86 | -0.84 | -3.44 | -3.27 |
| 90 Days Ago | -0.86 | -0.84 | -3.44 | -3.27 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 2 | 4 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | STRO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -8.20% | -- | -- | 5.40% |
| Next Qtr. | -15.60% | -- | -- | 10.90% |
| Current Year | -85.40% | -- | -- | 4.50% |
| Next Year | 1.20% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -12.88% | -- | -- | 10.94% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Piper Sandler: Overweight to Overweight | 4/3/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 4/3/2024 |
| Maintains | Truist Securities: Buy to Buy | 4/3/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 4/3/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 3/28/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 3/27/2024 |
Related Tickers
BCAB BioAtla, Inc.
2.5400
+12.89%
ITOS iTeos Therapeutics, Inc.
10.80
+1.89%
ADCT ADC Therapeutics SA
4.3400
-2.25%
REPL Replimune Group, Inc.
6.42
+4.39%
MRSN Mersana Therapeutics, Inc.
2.9400
+3.16%
ZYME Zymeworks Inc.
8.26
+1.85%
YMAB Y-mAbs Therapeutics, Inc.
14.71
-0.88%
ZNTL Zentalis Pharmaceuticals, Inc.
11.06
+0.68%
MGNX MacroGenics, Inc.
14.56
+1.32%
VINC Vincerx Pharma, Inc.
0.7300
-18.59%